Davide Matino

Assistant Professor
Division of Hematology & Thromboembolism, Department of Medicine, McMaster University, Ontario, Canada
Hamilton, Ontario, Canada

Presentation(s):

• PB0202 - Long-term effectiveness and safety of emicizumab in people with hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0287 - Successful Management of Recurrent Ankle Hemarthrosis in a Patient with Von Willebrand Disease Type 3 using Emicizumab: A Case Report

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 30.5 - Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or severe hemophilia B: updated results from the phase 3 BENEGENE-2 gene therapy trial

  Monday, June 24, 2024
  10:30 – 10:45 ICT

• PB0523 - Interim results from a non-interventional, post authorisation safety study of nonacog beta pegol as routine prophylaxis in patients with haemophilia B

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 40.2 - Incidence of thrombotic events in the fitusiran clinical development program

  Monday, June 24, 2024
  15:00 – 15:15 ICT

• OC 50.1 - First interim analysis of clinical outcomes in adults and adolescents with severe hemophilia A receiving efanesoctocog alfa prophylaxis in XTEND-ed, a phase 3 long-term extension study

  Tuesday, June 25, 2024
  09:30 – 09:45 ICT

• PB1199 - Acquired Hemophilia A: a single center experience.

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• OC 61.2 - Determinants of successful immune tolerance induction in people with severe hemophilia A

  Tuesday, June 25, 2024
  15:00 – 15:15 ICT